Roles of protein crotonylation in tumors: regulatory mechanisms and therapeutic potential
- 1Cancer Research Institute, The First Affiliated Hospital, Hengyang Medical School, University of South China
- 2Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, The First Affiliated Hospital, Hengyang Medical School, University of South China
- 3Department of Clinical Laboratory Medicine, Institution of Microbiology and Infectious Diseases, Hunan Province Clinical Research Center for Accurate Diagnosis and Treatment of High-incidence Sexually Transmitted Diseases, The First Affiliated Hospital, Hengyang Medical School, University of South China
Abstract
Lysine crotonylation(Kcr), an important protein post-translational modification, establishes a connection between cellular metabolism and epigenetic regulation. This modification utilizes crotonyl-CoA as a donor and is co-regulated by “writers”, “erasers” and “readers”. Furthermore, it participates in key biological processes including gene transcription, metabolic reprogramming, DNA damage repair, and remodeling of the tumor immune microenvironment. Recent studies have demonstrated that crotonylation is dysregulated in various malignant tumors, including breast cancer, colorectal cancer, liver cancer, lung cancer, and glioma. It drives tumor proliferation, invasion, metastasis, and drug resistance by influencing metabolic enzyme activity, chromatin status, DNA repair efficiency, and immune signaling pathways. Lysine crotonylation demonstrates significant environmental-dependence across different cancers; Not only can it promote the malignant phenotype of tumor cells, but it can also potentiate the response to immunotherapy under specific metabolic conditions. Preclinical studies have explored therapeutic strategies targeting tumor crotonylation, including metabolic interventions, enzymatic regulation, and combination immunotherapy; however, these approaches remain investigational and have not been clinically validated. This narrative review summarizes the molecular mechanisms, biological functions, and current advances of crotonylation in diverse malignancies, and highlights unresolved questions and emerging therapeutic hypotheses.
Related
- Epithelial-mesenchymal transition plasticity in breast cancer: regulatory mechanisms and therapeutic implications
- Lipid Metabolism and Ferroptosis in Cancer: Regulatory Mechanisms, Alternative Splicing, and Therapeutic Implications
- Thioredoxin system: mechanisms and therapeutic potential in mental disorders
- The therapeutic landscape of cannabidiol: a systematic review of molecular mechanisms, clinical efficacy in oncology and neurology, and regulatory changes.
- Dexmedetomidine as a potential neuroprotective agent against Alzheimer’s disease: molecular mechanisms and therapeutic perspectives
BibTeX
@article{liang2026roles,
title = {{Roles of protein crotonylation in tumors: regulatory mechanisms and therapeutic potential}},
author = {Yaqian Liang and Qinyue Liu and Can Yang and Yi Xun and Yanglin Liu and Yingying Shen and Xuyu Zu},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1952793},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1952793/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Roles of protein crotonylation in tumors: regulatory mechanisms and therapeutic potential
AU - Yaqian Liang
AU - Qinyue Liu
AU - Can Yang
AU - Yi Xun
AU - Yanglin Liu
AU - Yingying Shen
AU - Xuyu Zu
PY - 2026
DA - 2026/10/23
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1952793
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1952793/full
AB - Lysine crotonylation(Kcr), an important protein post-translational modification, establishes a connection between cellular metabolism and epigenetic regulation. This modification utilizes crotonyl-CoA as a donor and is co-regulated by “writers”, “erasers” and “readers”. Furthermore, it participates in key biological processes including gene transcription, metabolic reprogramming, DNA damage repair, and remodeling of the tumor immune microenvironment. Recent studies have demonstrated that crotonylation is dysregulated in various malignant tumors, including breast cancer, colorectal cancer, liver cancer, lung cancer, and glioma. It drives tumor proliferation, invasion, metastasis, and drug resistance by influencing metabolic enzyme activity, chromatin status, DNA repair efficiency, and immune signaling pathways. Lysine crotonylation demonstrates significant environmental-dependence across different cancers; Not only can it promote the malignant phenotype of tumor cells, but it can also potentiate the response to immunotherapy under specific metabolic conditions. Preclinical studies have explored therapeutic strategies targeting tumor crotonylation, including metabolic interventions, enzymatic regulation, and combination immunotherapy; however, these approaches remain investigational and have not been clinically validated. This narrative review summarizes the molecular mechanisms, biological functions, and current advances of crotonylation in diverse malignancies, and highlights unresolved questions and emerging therapeutic hypotheses.
SN - 1664-3224
ER -